Back to Search Start Over

The genomic architecture of antimalarial drug resistance.

Authors :
Cowell AN
Winzeler EA
Source :
Briefings in functional genomics [Brief Funct Genomics] 2019 Sep 24; Vol. 18 (5), pp. 314-328.
Publication Year :
2019

Abstract

Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that cause the majority of cases of human malaria, have developed resistance to nearly all known antimalarials. The ability of malaria parasites to develop resistance is primarily due to the high numbers of parasites in the infected person's bloodstream during the asexual blood stage of infection in conjunction with the mutability of their genomes. Identifying the genetic mutations that mediate antimalarial resistance has deepened our understanding of how the parasites evade our treatments and reveals molecular markers that can be used to track the emergence of resistance in clinical samples. In this review, we examine known genetic mutations that lead to resistance to the major classes of antimalarial medications: the 4-aminoquinolines (chloroquine, amodiaquine and piperaquine), antifolate drugs, aryl amino-alcohols (quinine, lumefantrine and mefloquine), artemisinin compounds, antibiotics (clindamycin and doxycycline) and a napthoquinone (atovaquone). We discuss how the evolution of antimalarial resistance informs strategies to design the next generation of antimalarial therapies.<br /> (© The Author(s) 2019. Published by Oxford University Press.)

Details

Language :
English
ISSN :
2041-2657
Volume :
18
Issue :
5
Database :
MEDLINE
Journal :
Briefings in functional genomics
Publication Type :
Academic Journal
Accession number :
31119263
Full Text :
https://doi.org/10.1093/bfgp/elz008